Strategic Acquisitions The company has a history of acquisition activity and was itself acquired by United Therapeutics, indicating potential appetite for partnerships or acquisition-led deals with larger players in parenteral delivery.

PatchPump Platform Core asset is the PatchPump technology enabling high-volume, high-viscosity, and biologic drug delivery, suggesting sales opportunities with large-dose therapies and device-integrated solutions in PAH and other parenteral areas.

PAH Focus Past emphasis on treprostinil delivery for pulmonary arterial hypertension signals a domain where complementary therapies, infusion devices, or combined drug-device offerings could align with existing relationships and clinical pathways.

Partnership Friendly A history of partnerships (Cardiome, Bespak) and a strategy to co-develop drug-device combos implies open channels for co-development deals, licensing, or OEM collaborations with device manufacturers and pharma.

Small Team, Niche niche With a lean workforce and specialized technology, there is potential to engage in pilot collaborations, quick-turnproof-of-concept projects, or contract development manufacturing for niche, high-value parenteral products.